- Biotechnology: stem cells and regenerative medicine
What is gene therapy?
Gene therapy treats a disease caused by a faulty gene by delivering a working copy of the gene, or an edit, into a patient's cells, usually with a harmless virus as the carrier, called a vector. The cells can be changed inside the body or taken out, changed and returned. It changes body cells only, so it is not passed to children.
The topic explained
A working copy for a faulty gene
Some diseases are caused by a single faulty gene: the cell lacks a working protein, such as an enzyme. Gene therapy aims to treat the cause by delivering a working copy of the gene into the cells that need it. For many such diseases one working copy is enough, which is why carriers, who have one faulty and one working copy, are usually healthy.
The first approved trial began at the US National Institutes of Health on 14 September 1990. The patient, Ashanti DeSilva, aged four, had ADA-SCID, a severe immune deficiency caused by a missing enzyme. Her white blood cells were given working copies outside her body and returned. The benefit was temporary and the treatment had to be repeated. A common misreading is that gene therapy changes every cell and is inherited. It changes only some somatic, body, cells; children inherit nothing from it. Changing eggs, sperm or embryos, germline therapy, is prohibited in many countries, Israel among them.
Viruses as delivery vans
A gene is a large, charged molecule that does not cross a cell membrane by itself. Viruses evolved to do exactly that, so most gene therapies use a viral vector: a virus whose own disease-causing genes have been removed and replaced by the therapeutic gene. Retroviruses and lentiviruses insert their DNA into the cell's chromosomes, so the gene passes to every daughter cell, which suits blood stem cells that keep dividing. Adenoviruses do not insert, so the effect fades. Adeno-associated virus, AAV, mostly stays outside the chromosomes but lasts for years in cells that rarely divide, such as those of the eye or nerves. A vector must also reach the right cells: different viruses, and different types of AAV, prefer different tissues, and how much vector is needed to reach enough target cells is a central question of safety.
Inside the body or outside it
In ex vivo therapy, cells are collected from the patient, given the gene in the laboratory, checked and returned. This suits blood, whose stem cells can be collected and returned by infusion. In in vivo therapy, the vector is injected into the patient. Luxturna, approved by the US FDA in 2017, carries a working RPE65 gene in AAV and is injected into the eye for an inherited form of blindness. Zolgensma, approved in 2019, carries a gene for spinal muscular atrophy type 1.
Not every approach adds a gene. Casgevy, approved in Britain and the United States in 2023, uses CRISPR to edit the patient's own blood stem cells outside the body, so that they make a form of hemoglobin that offsets sickle cell disease.
Setbacks that shaped the field
In 1999 Jesse Gelsinger, aged 18, died in a trial after an adenovirus vector set off a severe inflammatory reaction, and US trials were halted for a time. Between 2000 and 2002, children treated for X-SCID in a Paris trial developed a leukemia-like illness: the retroviral vector had inserted its DNA next to a gene that controls cell growth, called insertional mutagenesis. These events led to stricter oversight and safer vectors, and every new therapy now passes through trials in phases, starting with a few patients to test safety. Students sometimes conclude that gene therapy failed. It moved slowly, and several treatments are now approved; whether one suits a particular person is always a decision for doctors.
Practice: gene therapy
For 12th grade biotechnology students. Answer each question from the sheet, then check your answers.
Free, no sign-up. The answer key prints on the second page. Regenerating a new worksheet on the same topic needs a free account.
What does gene therapy deliver to a patient's cells, and for what kind of disease was it first designed?
Fill in the event of 1999 and say what it changed.
Fill in whether each vector joins the genome, and say which one suits blood stem cells that keep dividing.
Fill in step 3 of the ex vivo route and explain why it is possible outside the body but not inside.
Why is one working copy of a gene often enough to treat a recessive disease?
What happened in the X-SCID trial in Paris, and what is insertional mutagenesis?
A student says: a child of someone treated with gene therapy will inherit the new gene. Is that right?
Common questions
How does gene therapy work?
A working copy of a gene, or an edit, is carried into a patient's cells, usually by a virus whose disease genes were removed. The cells then make the protein that was missing.
What is a viral vector?
A virus whose own disease-causing genes have been removed and replaced with a therapeutic gene, used to carry the gene into cells, as viruses naturally carry their genes.
What is the difference between in vivo and ex vivo gene therapy?
In vivo, the vector is injected into the patient. Ex vivo, cells are collected, changed in the laboratory, checked and returned to the patient.
Is gene therapy the same as gene editing?
Not exactly. Classic gene therapy adds a working copy of a gene; gene editing, for example with CRISPR, changes the patient's own DNA. Both are used to treat disease in somatic cells.
When was the first gene therapy?
The first approved trial began at the US National Institutes of Health in September 1990, for a four-year-old girl with ADA-SCID, a severe immune deficiency.

Still have a question? Ask Lessi
Any question about this subject. Lessi answers right here, step by step.
Try asking
Asking needs a free account; your question is kept while you sign up. Answers are written by AI and can contain mistakes. Lessi doesn’t give medical or legal advice.
Learn it with a teacher
Learn this topic live with Lessi
Lessi, the AI teacher, explains it out loud on a board, with short quizzes, at your pace. The first 60 minutes are free.